Pfizer to pay record penalty in improper marketing case
The Obama administration put drugmakers on notice that they will be forced to atone for improper marketing practices as prosecutors unveiled a record $2.3 billion settlement with Pfizer. Officials at the departments of Justice and Health and Human Services called the agreement a cautionary example of their strategy to team up with states to police errant healthcare businesses. The Pfizer unit Pharmacia & Upjohn pleaded guilty to a single felony charge that accused the company of marketing its anti-inflammatory drug Bextra for broader uses and higher dosages than those approved by the Food and Drug Administration.
- Sharp HealthCare Leaves Pioneer ACO Program
- Acute Kidney Injury Gets New Focus
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Interventional Radiology No Longer a Sub-Specialty
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- PCI: Concerns Mount About Appropriateness
- Transforming Cancer Care
- MA an Insurance Proving Ground for Providers
- mHealth Tackles Readmissions